A STATISTICAL APPROACH TO DEVELOPMENT OF TASTE MASKED EFFERVESCENT TABLETS OF SILDENAFIL CITRATE CONTAINING KYRON T134

NISHANT OZA; SWATI SAGAR; AKRUTI KHODAKIYA; ASIT SAHU

doi:10.22159/ijap.2020v12i4.37624

Authors

NISHANT OZA C. U. Shah College of Pharmacy and Research, Wadhwan City, Gujarat, India
SWATI SAGAR C. U. Shah College of Pharmacy and Research, Wadhwan City, Gujarat, India
AKRUTI KHODAKIYA C. U. Shah College of Pharmacy and Research, Wadhwan City, Gujarat, India
ASIT SAHU C. U. Shah College of Pharmacy and Research, Wadhwan City, Gujarat, India

DOI:

https://doi.org/10.22159/ijap.2020v12i4.37624

Keywords:

Taste masking, Ion-exchange resin, Sildenafil citrate, Dispersible tablet, 32 full factorial design, kyron T134

Abstract

Objective: The aim of present work was to mask the bitter taste of sildenafil citrate by preparing drug resin complex (DRC) and develop sildenafil citrate 100 mg effervescent tablets.

Methods: Sildenafil citrate and kyron T134 complexes were prepared at different conditions and evaluated for taste and drug loading. Optimized DRC was use to formulate the dispersible tablet by direct compression technique. A 3² full factorial design was use to study the effect of effervescent agent (X₁) and croscarmellose sodium (X₂) on dispersion time (Y₁) and wetting time (Y₂). Factorial batches were also evaluated for thickness, hardness, content uniformity, friability, in vitro drug release and stability studies. Multiple linear regression analysis, ANOVA and graphical representation of the influence factor by 3D plots were performing by using sigma plot 11.0. A Check point batch was design according to the results of desirability value and evaluated for all the parameter

Results: FT-IR study confirm that sildenafil citrate and kyron T134 were compatible with each other. Among the various DRC batch B29 was found with less bitter and give a more drug loading. Checkpoint batch showed no significance difference between predicted value and actual value for dispersion time and wetting time and it was found stable during stability study.

Conclusion: Sildenafil citrate bitter tast was masked by kyron T134 and full factorial design result was indicate that independent variables have significant effect on dependent variables

Downloads

Download data is not yet available.

References

Bhowmik D, Chiranjib B, Krishnakanth P, Chandira RM. Fast dissolving tablet: an overview. J Chem Pharm Res 2009;1:163-77.

Paramita D, Arnabi G. Wafers: an innovative advancement of orodispersible films. Int J Appl Pharm 2016;8:1-7.

Sharma S, Lewis S. Taste masking technologies: a review. Int J Pharm Pharm Sci 2010;2:6-13.

Nanda A, Kandarapu R, Garg S. An update on taste masking technologies for oral pharmaceuticals. Indian J Pharm Sci 2002;64:10-7.

Boolell M, Allen MJ, Ballard SA. Sildenafil: an orally active type 5 cyclic GMPspecific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47–52

lodell CT Jr, Morey TE, Lobato EB, Aranda JM Jr, Staples ED, Schofield RS. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007;83:68–71.

Kumar RG, Sanghvi I. Optimization techniques: an overview for formulation development. Asian J Pharm Res 2015;5:217-21.

Nazmi M, Islam SMA, Bhuiyan MA, Reza MS. Effect of super disintegrants and their mode of incorporation on disintegration time and release profile of carbamazepine from an immediate-release tablet. J Appl Pharm Sci 2013;5:80-4.

Fatima SD, Komal S, Sholapur HN, Nanjundaswamy NG, Sajjanar VM. Design, optimization and evaluation of chewable tablets of clarithromycin using ion exchange resins. Indian J Pharm Sci 2016;78:818-26.

Faham A, Marechal D, Chenevier P. Orodispersible tablets containing fexofenadine, US Patent 6723348 B2; 2004.

Puttewar TY. Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin. J King Saud Univ 2010;22:229-40.

Anand V, Kandrapu R, Garg S. Preparation and evaluation of taste-masked orally disintegrating tablets of prednisolone. Asian J Pharma Sci 2007;6:227-38.

Al dhahir, RK Al-kotaji. Formulation of orally disintegrating tablets of cinnarizine by using direct compression method. Int J Appl Pharma 2019;11:117-23.

Patel BP, Patel JK, Rajput GC, Thakor RS. Formulation and evaluation of mouth dissolving tablets of cinnarizine. Indian J Pharm Sci 2010;72:522-5.

Yadav K, Yadav D, Srivastava A. Evaluation of hydrophilic, hydrophobic and waxy matrix excipients for sustained release tablets of venlafaxine hydrochloride. Drug Dev Ind Pharm 2013;39:1197-206.

Khar RK, Mohapatra S, Barik BB. Design and characterization of controlled release matrix tablets of Zidovudine. Asian J Pharm Clin Res 2009;2:54-61.

Madgulkar AR. Formulation and optimization of sustained release tablets of venlafaxine resinates using response surface methodology. Indian J Pharm Sci 2009;71:387-94.

Lakade SH, Bhalekar MR. Formulation and evaluation of sustained release matrix tablet of anti-anginal drug influence of combination of hydrophobic and hydrophilic matrix former. Res J Pharm Technol 2008;1:410-4.

Puttewar TY. Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin. King Saud Univ 2010;22:229-40.

Anand V, Kandrapu R, Garg S. Preparation and evaluation of taste-masked orally disintegrating tablets of prednisolone. Asian J Pharm Sci 2007;6:227-38.

Bolton S. Optimization techniques in pharmaceutical statistics. Practical and clinical Applications. 3rd ed. New York: Marcel Dekker; 1997.

Anthony NA. Pharmaceutical experimental design and interpretation. 2nd ed. Taylor and Francis Group; 2006.

Lionberger RA, Lee SL, Lee L. Quality by design: concepts for ANDAs. Adv Appl Pharm Sci J 2008;10:268-76.

Guideline ICH. Stability testing guidelines: stability testing of new drug substances and products. ICH Q1A (R2) (CPMP/ICH/2736/99); 1999.

Singh S. Stability testing during product development. In: Jain NK. Pharmaceutical product development. CBS publisher and distributors India; 2000. p. 272-93.

Bajaj S, Singhla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci 2012;2 Suppl 3:129-38.

Vogel AI. Vogel's textbook of quantitative chemical analysis. 5th ed. Jeffrey GH, Bassett J, Mendham J, Denney R. editors; 1989. p. 220-5.

Nagar P, Singh K, Chauhan I, Madhu V, Yasir M, Khan A, et al. Orally disintegrating tablets: formulation, preparation, techniques, and evaluation. J Appl Pharm Sci 2011;4:35-45.

Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical experimental design. New York: Marcel Dekker; 1999. p. 191-8.

Anthony NA. Pharmaceutical experimental design and interpretation. 2nd ed. Taylor and Francis Group; 2006.

Khanam N, Alam MI, MD Yusuf Ali, QMAI Siddiqui, A Ur Rahman. A review on optimization of drug delivery system with experimental designs. Int JAppl Pharma 2018;10:7-12.